AR097078A1 - Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto - Google Patents
Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuestoInfo
- Publication number
- AR097078A1 AR097078A1 ARP140102788A ARP140102788A AR097078A1 AR 097078 A1 AR097078 A1 AR 097078A1 AR P140102788 A ARP140102788 A AR P140102788A AR P140102788 A ARP140102788 A AR P140102788A AR 097078 A1 AR097078 A1 AR 097078A1
- Authority
- AR
- Argentina
- Prior art keywords
- hydroxy
- corticosteroid
- inhibitors
- compound
- maba
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003246 corticosteroid Substances 0.000 title abstract 3
- 229940043355 kinase inhibitor Drugs 0.000 abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 abstract 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 abstract 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 abstract 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229950000210 beclometasone dipropionate Drugs 0.000 abstract 1
- 229960004436 budesonide Drugs 0.000 abstract 1
- 229960003728 ciclesonide Drugs 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- GUTQMBQKTSGBPQ-UHFFFAOYSA-N dithiophen-2-ylmethanone Chemical group C=1C=CSC=1C(=O)C1=CC=CS1 GUTQMBQKTSGBPQ-UHFFFAOYSA-N 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229960001469 fluticasone furoate Drugs 0.000 abstract 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 abstract 1
- 229960000289 fluticasone propionate Drugs 0.000 abstract 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229960002744 mometasone furoate Drugs 0.000 abstract 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 abstract 1
- 230000003551 muscarinic effect Effects 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229960005294 triamcinolone Drugs 0.000 abstract 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una combinación que comprende (a) un corticosteroide y (b) un compuesto dual antagonista muscarínico - agonista b2 adrenérgico que es hidroxi(di-2-tienil)acetato de trans-4-[{3-[5-({[(2R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-iI)etil]amino}metil)-1H-1,2,3-benzotriazoI-1-iI]propil}(metil)amino]ciclohexilo, o cualquier sal o solvato farmacéuticamente aceptable del mismo. Reivindicación 3: Una combinación según la reivindicación 1 ó 2, en donde el corticosteroide seselecciona del grupo que comprende budesonida, dipropionato de beclometasona, triamcinolona, furoato de mometasona, ciclesonida, propionato de fluticasona y furoato de fluticasona. Reivindicación 10: Una combinación según una cualquiera de las reivindicaciones precedentes, que comprende además (c) otro compuesto activo seleccionado de: (i) inhibidores de PDE IV, (ii) antagonistas de Ieucotrieno D4, (iii) inhibidores de egfr-quinasa, (iv) inhibidores de quinasa p38, (v) inhibidores de JAK y (vi) agonistas del receptor NK1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382305 | 2013-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR097078A1 true AR097078A1 (es) | 2016-02-17 |
Family
ID=48917475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102788A AR097078A1 (es) | 2013-07-25 | 2014-07-25 | Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10456390B2 (es) |
| EP (1) | EP3024459B1 (es) |
| JP (1) | JP6501774B2 (es) |
| CN (1) | CN105407890B (es) |
| AR (1) | AR097078A1 (es) |
| ES (1) | ES2727526T3 (es) |
| TW (1) | TW201517906A (es) |
| UY (1) | UY35677A (es) |
| WO (1) | WO2015011245A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| ES2750523T3 (es) | 2012-12-18 | 2020-03-26 | Almirall Sa | Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| BR112020007808A2 (pt) | 2017-10-20 | 2020-10-20 | Chiesi Farmaceutici S.P.A. | formulações farmacêuticas que compreendem um agonista de receptor de opioide como ingrediente ativo, métodos de fabricação e usos terapêuticos destas |
| CN113544121A (zh) * | 2019-06-06 | 2021-10-22 | 中国医药研究开发中心有限公司 | 具有β2受体激动及M受体拮抗活性的杂环衍生物及其医药用途 |
| CN110169969B (zh) * | 2019-06-28 | 2022-05-27 | 南京医科大学 | Mk571在制备预防和治疗心脏病药物中应用 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1212742B (it) | 1983-05-17 | 1989-11-30 | Dompe Farmaceutici Spa | Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica |
| DE3370320D1 (en) | 1983-09-26 | 1987-04-23 | Magis Farmaceutici | Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them |
| CA2024789C (en) | 1989-09-07 | 2001-02-06 | Malcolm Johnson | Compounds for the treatment of inflammation and allergy |
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| US6124354A (en) | 1996-07-29 | 2000-09-26 | Pharmacia & Upjohn Ab | Arylcycloalkane carboxylic esters, their use, pharmaceutical compositions and preparation |
| AU4248597A (en) | 1996-09-06 | 1998-03-26 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
| SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
| JP2003525855A (ja) * | 1998-08-27 | 2003-09-02 | ブリストル−マイヤーズ スクイブ カンパニー | 新規な薬剤塩形態 |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| CN1237051C (zh) | 1999-08-20 | 2006-01-18 | 道农业科学公司 | 杀真菌的杂环芳族酰胺和它们的组合物、使用方法和制备 |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| EP1615881A2 (en) | 2003-04-01 | 2006-01-18 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| ES2329133T3 (es) | 2003-05-28 | 2009-11-23 | Theravance, Inc. | Compuestos azabicicloalcanicos como antagonistas de receptores de muscarinicos. |
| US7320990B2 (en) | 2004-02-13 | 2008-01-22 | Theravance, Inc. | Crystalline form of a biphenyl compound |
| DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| WO2006023457A1 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| KR20080036632A (ko) | 2005-08-08 | 2008-04-28 | 아젠터 디스커버리 리미티드 | 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도 |
| WO2007045979A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
| GB0602778D0 (en) | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| CA2643097C (en) | 2006-03-20 | 2012-03-13 | Pfizer Limited | Amine derivatives |
| GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| WO2008017827A2 (en) | 2006-08-08 | 2008-02-14 | Argenta Discovery Limited | Azole and thiazole derivatives and their uses |
| GB0702384D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | Chemical compounds |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| MX2009002209A (es) | 2006-10-04 | 2009-03-16 | Pfizer Ltd | Derivados de sulfonamida. |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| GB0700972D0 (en) | 2007-01-18 | 2007-02-28 | Imp Innovations Ltd | Treatment of inflammatory disease |
| WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
| GB0702413D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
| WO2008149110A1 (en) | 2007-06-08 | 2008-12-11 | Argenta Discovery Limited | Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated |
| PE20090907A1 (es) | 2007-07-21 | 2009-08-05 | Boehringer Ingelheim Int | Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente |
| WO2009017813A1 (en) | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
| UA100400C2 (uk) | 2008-02-06 | 2012-12-25 | Астразенека Аб | Похідні спіроциклічних амідів |
| CN101544572B (zh) | 2008-03-26 | 2013-03-20 | 连云港恒邦医药科技有限公司 | 一种氨溴索衍生物及其制备方法 |
| KR100990872B1 (ko) | 2008-05-06 | 2010-10-29 | 한국화학연구원 | 신규한 1-페닐-카르복실산 에스테르 유도체 또는 이의약학적으로 허용가능한 염, 이의 제조방법 및 이를유효성분으로 함유하는 무스카린 수용체 길항제 또는유기인 화합물 중독에 의한 신경계 질환 예방 및 치료용약학적 조성물 |
| GB0808708D0 (en) | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| EP2303266A4 (en) | 2008-06-20 | 2015-01-21 | Astrazeneca Ab | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7-YLE COMPOUND FOR THE MODULATION OF BETA-2-ADRENORECEPTOR ACTIVITY |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| WO2010011813A1 (en) * | 2008-07-23 | 2010-01-28 | Alkermes, Inc. | Complex of trospium and pharmaceutical compositions thereof |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| MX2011011156A (es) | 2009-04-23 | 2011-11-04 | Theravance Inc | COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2. |
| CA2760630A1 (en) | 2009-04-30 | 2010-11-04 | Teijin Pharma Limited | Quaternary ammonium salt compounds |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| GB201002612D0 (en) | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| AR083115A1 (es) | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| ES2552538T3 (es) | 2011-06-10 | 2015-11-30 | Chiesi Farmaceutici S.P.A. | Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico |
| BR112013030302B1 (pt) | 2011-06-10 | 2021-08-24 | Chiesi Farmaceutici S.P.A. | Composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| UA111867C2 (uk) | 2011-11-11 | 2016-06-24 | Аллерган, Інк. | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ |
| UA123760C2 (uk) | 2011-11-11 | 2021-06-02 | Гіліад Аполло, Ллс | Сполука (варіанти) та композиція, що містить сполуку |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| MD20140044A2 (ro) | 2011-11-11 | 2014-08-31 | Pfizer Inc. | 2-Tiopirimidinone şi utilizarea lor pentru tratamentul afecţiunilor cardiovasculare |
| WO2014086927A1 (en) | 2012-12-06 | 2014-06-12 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| GEP20186839B (en) | 2012-12-06 | 2018-04-10 | Chiesi Farma Spa | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| MX2015007556A (es) | 2012-12-18 | 2015-10-20 | Vertex Pharma | Derivados de manosa para tratar infecciones bacterianas. |
| ES2750523T3 (es) | 2012-12-18 | 2020-03-26 | Almirall Sa | Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3 |
| ES2700226T3 (es) | 2012-12-18 | 2019-02-14 | Chiesi Farm Spa | Derivados de 3-oxo-2,3,5,8-tetrahidro-[1,2,4]triazolo[4,3-a]pirimidina para el tratamiento de enfermedades respiratorias |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201440768A (zh) | 2013-02-27 | 2014-11-01 | Almirall Sa | 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
-
2014
- 2014-07-22 TW TW103125076A patent/TW201517906A/zh unknown
- 2014-07-24 ES ES14742248T patent/ES2727526T3/es active Active
- 2014-07-24 WO PCT/EP2014/065966 patent/WO2015011245A1/en not_active Ceased
- 2014-07-24 JP JP2016528539A patent/JP6501774B2/ja not_active Expired - Fee Related
- 2014-07-24 US US14/906,957 patent/US10456390B2/en not_active Expired - Fee Related
- 2014-07-24 CN CN201480042034.5A patent/CN105407890B/zh not_active Expired - Fee Related
- 2014-07-24 EP EP14742248.9A patent/EP3024459B1/en active Active
- 2014-07-25 AR ARP140102788A patent/AR097078A1/es unknown
- 2014-07-25 UY UY35677A patent/UY35677A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20160175295A1 (en) | 2016-06-23 |
| TW201517906A (zh) | 2015-05-16 |
| ES2727526T3 (es) | 2019-10-16 |
| CN105407890A (zh) | 2016-03-16 |
| UY35677A (es) | 2015-02-27 |
| JP6501774B2 (ja) | 2019-04-17 |
| JP2016527245A (ja) | 2016-09-08 |
| US10456390B2 (en) | 2019-10-29 |
| CN105407890B (zh) | 2019-06-07 |
| EP3024459B1 (en) | 2019-03-27 |
| WO2015011245A1 (en) | 2015-01-29 |
| EP3024459A1 (en) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097078A1 (es) | Combinaciones que comprenden compuestos maba y corticosteroides, uso, kit y compuesto | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| DOP2019000117A (es) | Nuevos derivados de quinolina | |
| MX378315B (es) | Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| MX2019005009A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas. | |
| BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
| BR112015020302A2 (pt) | derivado de pirazol | |
| UY37831A (es) | Nuevos derivados de quinolina | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| DOP2019000275A (es) | Nuevos derivados de pirazol bicíclicos | |
| CL2020002891A1 (es) | Nuevos derivados de quinolina | |
| BR112017016817A2 (pt) | derivados heterocíclicos formilados como inibidores de fgfr4 | |
| PL3820446T3 (pl) | Kompozycje farmaceutyczne zawierające rpl554 w hfa-134a do podawania przez inhalację | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| EA201990765A1 (ru) | Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок | |
| DOP2013000314A (es) | Composición farmacéutica oftalmológica tópica que contiene regorafenib | |
| MX2023006235A (es) | Composiciones para administracion de farmacos y metodos de uso de las mismas. | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| HK1246288A1 (zh) | S1pr2拮抗剂及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |